Role of Neuronal Guidance Proteins as Diagnostic Markers for Acute Kidney Injury (AKI)

Acute Kidney Injury Clinical Trial

— NEUKID  

Official title:

Role of Neuronal Guidance Proteins as Diagnostic Markers for Acute Kidney Injury (AKI)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05924269
• Other study ID #: NEUKID
• Status: Not yet recruiting
• Start date: August 2023
• Est. completion date: July 2026

Study information

• Verified date: June 2023
• Source: University Hospital Tuebingen
• Contact: Andreas Körner, MD
• Phone: +497071-29 61783
• Email: andreas.koerner[@]med.uni-tuebingen.de
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Acute kidney failure remains one of the most challenging entities to diagnose in clinical medicine, especially in the field of intensive care. The diagnosis of acute kidney injury is based solely on urine output and serum creatinine, both of which could also be influenced by other factors. A more sensitive and faster diagnostic option would not only be desirable but of utmost clinical importance. Therefore, the investigators aim to identify Neuronal Guidance Proteins (NGPs) as potential biomarkers for the identification and early detection of AKI with this investigation. This investigation aims to identify the possibility of diagnosing acute kidney injury, the subsequent validation of a potential biomarker will then have to take place in a multicenter study approach: Data in preclinical mouse models suggest that SEMA7A as one of the NGPs could be valuable as a biomarker, the study now aims to attempt a preliminary survey in humans and measure various NGPs.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 600
• Est. completion date: July 2026
• Est. primary completion date: July 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patients undergoing cardiac surgery

• written consent

Exclusion Criteria:

• no written consent possible

• Polytrauma, severe burns

• Immunosuppression

• Pregnancy

• Diagnosis of Hepatitis B, Hepatitis C, and/or HIV

• Sepsis

• Pre-existing kidney damage

Related Conditions & MeSH terms

• Acute Kidney Injury
• Wounds and Injuries

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Tuebingen

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AKI	Development of AKI after cardiac surgery	1-7 days
Secondary	NGP	Concentration of NGPs in Blood and Urine	1-7 days